Category:Adult
Status:Active
Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
We are studying whether men being treated for prostate cancer have the same amount of side effects from either one of two different external radiation treatments: IMRT or PBT. With IMRT, a number o...
Diagnosis: Prostate Cancer
Phase: 3
Protocol Number: 11-497
The purpose of this study is to determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in m...
Diagnosis: Prostate Cancer, Radiation Oncology
Phase: 3
Protocol Number: 15-038
The purpose of this study is to look for markers of how Ra-223 improves the lives of men with prostate cancer. This study makes use of Ra-223 in the standard FDA-approved way, but adds non-standard...
Diagnosis: Prostate Cancer
Phase: 2
Protocol Number: 14-375
A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer
This research study is studying the use of a targeted therapy called LY SARM, which is an investigational drug from a new class of molecules called Selective Androgen Receptor Modulators (SARMs) as...
Diagnosis: Prostate Cancer
Phase: 2
Protocol Number: 15-120
A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY3023414 in combination with enzalutamide in men with prostate cancer.
Diagnosis: Prostate Cancer
Phase: 2
Protocol Number: 15-453
NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
This study is a Phase 1/2 open-label involving 2 groups of patients newly diagnosed with either unfavorable intermediate risk or high risk prostate adenocarcinoma. One group will receive only EBRT ...
Diagnosis: Radiation Oncology, Prostate Cancer
Phase: 1 / 2
Protocol Number: 16-445
Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy
This study will evaluate a method to detect tumor cells that are circulating in the blood without getting a biopsy. The investigators already know from other studies that cancer tumors shed a small...
Diagnosis: Prostate Cancer
Phase: N/A
Protocol Number: 08-207
Focal MR-Guided Focused Ultrasound Treatment of Localized Low and Intermediate Risk Prostate Cancer
The hypothesis of this feasibility study is that focal treatment with ExAblate MRgFUS has the potential to be an effective non-invasive treatment for low risk, organ-confined prostate cancer, with ...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 13-184
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) re...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 16-493
Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy
This research study is evaluating the impact and feasibility of a 12-week brisk walking and moderate strength training exercise intervention including a virtual component in men who are initiating ...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 16-515
The purpose of this study is to determine if apalutamide plus gonadotropin releasing hormone (GnRH) agonist in participants with high-risk, localized or locally advanced prostate cancer receiving p...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 16-244
A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer
This research study is studying a combination of drugs as a possible treatment for castration-resistant prostate cancer. The interventions involved in this study are: - Docetaxel (a type of chemoth...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 16-485
This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with castration-resistant prostate cancer that has spread to other places in the body. ...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 17-710
Genetic Counseling Processes and Outcomes Among Males With Prostate Cancer (ProGen)
This randomized controlled trial aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 17-409
The study aims to evaluate the combination of GSK525762 with other agents that have been shown to be effective in the treatment of CRPC or metastatic CRPC, including approved agents (e.g., abirater...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 17-369
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 17-384
This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate ca...
Diagnosis: Prostate Cancer, Radiation Oncology
Phase:
Protocol Number: 16-623
This phase Ib trial studies the side effects and best dose of niraparib when given together with radium Ra223 dichloride in treating patients with prostate cancer that keeps growing even when the a...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 17-698
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors
Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), trip...
Diagnosis: Breast: Early Stage Disease, GYN: Ovarian, Fallopian, Peritoneal Cancer, Lung Cancer, Solid Tumor/Phase I, Prostate Cancer
Phase:
Protocol Number: 17-687
This is a two-arm, open label phase 1b/2 with an oral administration of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone in male patients with metastatic Castration This s...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 18-112
The purpose of the phase 2 study is to determine whether PCM-075 given orally once daily for 5 consecutive days every 21 days is safe and tolerable in adult patients with Metastatic Castration-Resi...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 18-117
The purpose of this study is to test if treatment with medications that reduce the male hormone level in the participant's body for a few months before surgery can shrink prostate cancer as mu...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 18-429
Mobile Health App to Mitigate the Metabolic Effects of Androgen Deprivation Therapy
This research study seeks to develop and evaluate a mobile health app which aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise prog...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 17-692
Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer
The primary objective of this study is to compare overall survival (OS) in patients with progressive PSMA-positive mCRPC who receive 177Lu-PSMA-617 in addition to best supportive/best standard of c...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 18-425
Muscadine Plus (MPX) In Men With Prostate Cancer
This research is being done to determine if men with rising PSA after initial therapy for localized prostate cancer who display the Alanine/Alanine SOD2 genotype of MnSOD and supplement their diet ...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 18-525
Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of l...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 18-733
This phase II trial studies how well multiparametric magnetic resonance imaging (MRI) works in evaluating cancer stage and helping treatment planning in patients with prostate cancer. Multiparametr...
Diagnosis: Prostate Cancer
Phase:
Protocol Number: 18-742